A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects

Trial Profile

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs GLPG 2222 (Primary) ; GLPG 2451 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Galapagos NV
  • Most Recent Events

    • 10 Jul 2017 Protocol amended with change in study design:intervention model changed from crossover to sequential.
    • 10 Jul 2017 Status changed from recruiting to completed.
    • 22 Mar 2017 According to Galapagos NV media release, company is planning to add corrector GLPG2737 to make a triple combination, which will first be evaluated in healthy volunteers and then in patients with the F508del mutation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top